Janel Long-Boyle, PharmD, PhD

Phone: +1 415 640-1569
600 16th Street, Rm 001
UCSF Box 0613
San Francisco, CA 94158
United States

What I do

I am a translational scientist with research interests that include pediatric cancer therapeutics, pharmacokinetics, pharmacodynamics, pharmacogenomics, and clinical trial design. The majority of my research is focused around the chemotherapeutic and immunosuppressive agents used in the conditioning regimens of pediatric hematopoietic cell transplantation (HCT). Specifically, I am interested in how patient specific covariates such as age, renal function, or genetic variants involved in drug metabolism or distribution may influence drug clearance in the pediatric HCT population.

Departmental research area

My research expertise

pharmacokinetics, pharmacodynamics, Pediatric Pharmacology, pediatric hematology, Oncology, bone marrow transplantation

Clinical expertise

hematology, Oncology, bone marrow transplantation

Professional background

Biography

Dr. Boyle is a translational scientist with research interests that include pediatric cancer therapeutics, pharmacokinetics, pharmacodynamics, pharmacogenomics, and clinical trial design. The majority of her research resides within the complex setting of hematopoietic cell transplantation (HCT) and is focused around chemotherapeutic and immunosuppressive agents used in the preparative regimens of pediatric HCT. Specifically, Dr. Boyle studies how covariates such as age, renal function, or genetic variants involved in drug metabolism or distribution may influence drug clearance in the pediatric HCT population.

Research keywords

  • Oncology
  • Pharmacokinetics-Pharmacodynamics
  • Hematopoietic Cell Transplantation
  • Hematology
  • Pediatric Pharmacology
  • Mycophenolic Acid
  • Chimerism
  • Hematologic Neoplasms
  • Adenine Nucleotides
  • Arabinonucleosides
  • Neoplasms, Second Primary
  • Hematopoietic Stem Cell Transplantation
  • Immunosuppressive Agents
  • Transplantation Conditioning
  • Biological Models
  • Busulfan
  • Graft vs Host Disease
  • Melphalan
  • Vidarabine
  • Antineoplastic Agents, Alkylating